Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

• Christoph Kornauth,
• Charles Herbaux,
• Bernd Boidol,
• Chantal Guillemette,
• Patrick Caron,
• Marius E. Mayerhöfer,
• Stéphanie Poulain,
• Olivier Tournilhac,
• Tea Pemovska,
• Stephen J.F. Chong,
• Emiel van der Kouwe,
• Lukas Kazianka,
• Georg Hopfinger,
• Daniel Heintel,
• Roland Jäger,
• Markus Raderer,
• Ulrich Jäger,
• Ingrid Simonitsch-Klupp,
• Wolfgang R. Sperr,
• Stefan Kubicek,
• Matthew S. Davids,
• Philipp B. Staber

Affiliations

Christoph Kornauth

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Charles Herbaux

Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston

Bernd Boidol

Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna

Chantal Guillemette

Centre Hospitalier Universitaire de Québec – Université Laval and Faculty of Pharmacy, Université Laval, Québec

Patrick Caron

Centre Hospitalier Universitaire de Québec – Université Laval and Faculty of Pharmacy, Université Laval, Québec

Marius E. Mayerhöfer

Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna

Stéphanie Poulain

UMR CANTHER, INSERM 1277-CNRS 9020 UMRS 12. University of Lille, Hematology Laboratory, Biology and pathology center, CHU de Lille, 59000 Lille

Olivier Tournilhac

Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC1405, Clermont Ferrand

Tea Pemovska

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Stephen J.F. Chong

Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston

Emiel van der Kouwe

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Lukas Kazianka

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Georg Hopfinger

3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna

Daniel Heintel

1. Medical Department, Center for Oncology and Hematology, Wilhelminenhospital Vienna, Vienna

Roland Jäger

Department of Laboratory Medicine, Medical University of Vienna

Markus Raderer

Department of Medicine I, Division of Oncology, Medical University of Vienna

Ulrich Jäger

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Ingrid Simonitsch-Klupp

Clinical Department of Pathology, Medical University of Vienna

Wolfgang R. Sperr

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna

Stefan Kubicek

Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna

Matthew S. Davids

Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston

Philipp B. Staber

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna